Author:
Tsotinis Andrew,P. Papanastasiou Ioannis
Reference58 articles.
1. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT 1 and MT 2 melatonin receptors: Ligands, models, oligomers, and therapeutic potential. Journal of Medicinal Chemistry. 2014;57(8):3161-3185. Available from: https://pubs.acs.org/doi/10.1021/jm401343c
2. Oishi A, Cecon E, Jockers R. Melatonin receptor signaling: Impact of receptor oligomerization on receptor function. In: International Review of Cell and Molecular Biology. Cambridge, MA, United States: Elsevier; 2018. pp. 59-77. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1937644818300121
3. Gobbi G, Comai S. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. Journal of Pineal Research. 2019;66(3):e12544. Available from: http://doi.wiley.com/10.1111/jpi.12544
4. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacological Reviews. 2010;62(3):343-380. Available from: http://pharmrev.aspetjournals.org/lookup/doi/10.1124/pr.110.002832
5. Stauch B, Johansson LC, McCorvy JD, Patel N, Han GW, Huang X-P, et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. Nature. 2019;569(7755):284-288. Available from: http://www.nature.com/articles/s41586-019-1141-3